![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 7
Zeitschriftenartikel
Turner, N. C.; Slamon, D. J.; Ro, J.; Bondarenko, I; Im, S-A; Masuda, N.; Colleoni, M.; DeMichele, A.; Loi, S.; Verma, S.; Iwata, H.; Harbeck, N.; Loibl, S.; Andre, F.; Puyana Theall, K.; Huang, X.; Giorgetti, C.; Huang Bartlett, C. und Cristofanilli, M.
(2018):
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
In: New England Journal of Medicine, Bd. 379, Nr. 20: S. 1926-1936
Dieras, V.; Harbeck, N.; Joy, A. A.; Gelmon, K. A.; Ettl, J.; Verma, S.; Lu, D.; Gauthier, E. R.; Schnell, P.; Mori, A.; Rugo, H. S. und Finn, R. S.
(2017):
PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) first-line advanced breast cancer (ABC) receiving palbociclib plus letrozole (P plus L).
In: Annals of Oncology, Bd. 28
Baselga, J.; Cortés, J.; De Laurentiis, M.; Diéras, V.; Harbeck, N.; Hsu, J.; Jin, H.; Schimmoller, F.; Wilson, T. R.; Im, Y.-H.; Jacot, W.; Krop, I. E. und Verma, S.
(2016):
SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors.
In: Cancer Research, Bd. 76
Verma, S.; DeMichele, A. M.; Loi, S.; Ro, J.; Colleoni, M.; Iwata, H.; Harbeck, N.; Stearns, V.; Cristofanilli, M.; Huang Bartlett, C.; Schnell, P.; Zhang, K.; Thiele, A.; Turner, N. C. und Rugo, H. S.
(2016):
Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.
In: Cancer Research, Bd. 76
Harbeck, N.; Iyer, S.; Turner, N.; Cristofanilli, M.; Ro, J.; André, F.; Loi, S.; Verma, S.; Iwata, H.; Bhattacharyya, H.; Theall, K. Puyana; Bartlett, C. H. und Loibl, S.
(2016):
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.
In: Annals of Oncology, Bd. 27, Nr. 6: S. 1047-1054
Loibl, S.; Demichele, A.; Turner, N. M.; Cristofanilli, M.; Loi, S.; Verma, S.; Bhattacharyya, H.; Ke, Z.; Giorgetti, C.; Bartlett, C. H.; Iyer, S.; Colleoni, M.; Masuda, N.; Im, S.-A. und Harbeck, N.
(2016):
Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR +, HER2-metastatic breast cancer.
In: Annals of Oncology, Bd. 27
Baselga, J.; Cortes Castan, J.; De Laurentiis, M.; Dieras, V.; Harbeck, N.; Hsu, J.; Jin, H.; Schimmoller, F.; Wilson, T. R.; Im, Y.-H.; Jacot, W.; Krop, I. E. und Verma, S.
(2016):
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours.
In: Annals of Oncology, Bd. 27